Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.41 |
| ▸ | JAK2 | O60674 | 6/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489171 | 1.00 | JAK3 (0.41) | JAK3JAK2PDE4DTDP1GFER | |
| SCHEMBL23084452 | 1.00 | JAK3 (0.41) | JAK3JAK2PDE4DTDP1GFER | |
| SCHEMBL29489168 | 1.00 | JAK3 (0.41) | JAK3JAK2PDE4DTDP1GFER | |
| SCHEMBL21098279 | 1.00 | JAK3 (0.41) | JAK3JAK2PDE4DTDP1GFER | |
| SCHEMBL29489173 | 0.94 | JAK2 (0.42) | JAK3JAK2PDE4DTDP1KMT2A | |
| SCHEMBL28472769 | 0.94 | JAK2 (0.42) | JAK3JAK2PDE4DTDP1KMT2A | |
| SCHEMBL21098225 | 0.94 | JAK2 (0.42) | JAK3JAK2PDE4DTDP1KMT2A | |
| SCHEMBL23084516 | 0.94 | JAK2 (0.42) | JAK3JAK2PDE4DTDP1KMT2A | |
| SCHEMBL29489172 | 0.94 | JAK2 (0.42) | JAK3JAK2PDE4DTDP1KMT2A | |
| SCHEMBL8256499 | 0.90 | PIM1 (0.40) | KMT2ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111712502-B | Substituted azetidine dihydro-thienopyrimidines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| CN-111712502-A | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-09-25 | — | — | CN | disclosed |
| WO-2019115774-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE5A, PDE3A | JAK3 2612/4885JAK2 1796/4885PDE4D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.